AlzMed

JP

Topics

トピックス
We will present a poster at the 14th Alzheimer’s & Parkinson’s Drug Development Summit, to be held in Boston in February next year.
A paper on MCI diagnosis using Syncheck has been accepted for publication (in press) in the Journal of Alzheimer’s Disease.
An essay in Japanese by our CEO, Dr. Tomoaki Shirao, titled “The Path of Neurochemistry Traveled with Drebrin,” has been published in Volume 64, Issue 1 of Neurochemistry.
AlzMed Inc. to Present Novel ELISA “Syncheck™” for Memory Function Monitoring at the 48th Annual Meeting of the Japan Neuroscience Society (July 25, 2P-369).
Our CSO, Yuko Sekino (Project Professor at the University of Tokyo), will speak at CPHI Japan (Tokyo Big Sight) on “A Japan-Driven Breakthrough in MCI Treatment: Drebrin Drug Discovery from Memory Research.
The Funakoshi website has been updated with new details on the anti-drebrin antibody, M2F6-Shirao.
Our diagnostic project has been selected for AMED’s FY2025 Medical Device Development Promotion Research Program.
We exhibited a booth at Japan Night held in San Francisco on January 13, 2025.
AlzMed Products Now Available through Funakoshi – Featuring Drebrin Antibody and Frozen Rat Primary Hippocampal Neurons
Our patent for an animal model of Alzheimer’s disease has been registered.
1 2